Skip to content
Disclosery

Northpond Ventures, LLC

Follow

13F filer, CIK 1911245, Bethesda, MD

Northpond Ventures, LLC reported $43,659,366 across 3 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2024-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-24-118975

Period
2024-09-30
Reported value
$43.7M
Holdings
3
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TBIOexited-546,897-$2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2024

Share positions as resolved from 13F-HR 0001104659-24-118975, largest first. % of portfolio is the value over $43,659,366, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 3,255,426 shares; 2024Q2: 3,255,426 shares; 2024Q3: 3,255,426 shares 3,255,426$15.9M36.46%0Timeline
VIGIL NEUROSCIENCE INCVIGIL NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: 4,214,498 shares; 2023Q1: 4,214,498 shares; 2023Q2: 4,214,498 shares; 2023Q3: 4,214,498 shares; 2023Q4: 4,214,498 shares; 2024Q1: 4,214,498 shares; 2024Q2: 4,214,498 shares; 2024Q3: 4,214,498 shares 4,214,498$14.3M32.82%0
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: 1,935,215 shares; 2023Q1: 1,935,215 shares; 2023Q2: 1,935,215 shares; 2023Q3: 1,935,215 shares; 2023Q4: 1,935,215 shares; 2024Q1: 1,935,215 shares; 2024Q2: 1,935,215 shares; 2024Q3: 1,935,215 shares 1,935,215$13.4M30.72%0Timeline

Sold out in Q3 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TBIOTELESIS BIO INC546,897$2Mshares

How Q3 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-24-118975 base2024-11-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001104659-24-118975 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001104659-24-089657 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001104659-24-061943 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001104659-24-023717 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001104659-23-118119 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001104659-23-091394 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001104659-23-060801 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001104659-23-009328 Quarter ended 2022-12-312023-02-01acceptance time not in the bulk data set
13F-HR 0001104659-22-117428 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001104659-22-084803 Quarter ended 2022-06-302022-08-01acceptance time not in the bulk data set
13F-HR 0001104659-22-060755 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001104659-22-023765 Quarter ended 2021-12-312022-02-15acceptance time not in the bulk data set